283 related articles for article (PubMed ID: 23612435)
1. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.
Crist RC; Clarke TK; Ang A; Ambrose-Lanci LM; Lohoff FW; Saxon AJ; Ling W; Hillhouse MP; Bruce RD; Woody G; Berrettini WH
Neuropsychopharmacology; 2013 Sep; 38(10):2003-10. PubMed ID: 23612435
[TBL] [Abstract][Full Text] [Related]
2. A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence.
Crist RC; Doyle GA; Nelson EC; Degenhardt L; Martin NG; Montgomery GW; Saxon AJ; Ling W; Berrettini WH
Pharmacogenomics J; 2018 Jan; 18(1):173-179. PubMed ID: 27958381
[TBL] [Abstract][Full Text] [Related]
3. A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder.
Kranzler HR; Lynch KG; Crist RC; Hartwell E; Le Moigne A; Laffont CM; Andorn AC
Int J Neuropsychopharmacol; 2021 Feb; 24(2):89-96. PubMed ID: 32920647
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.
Clarke TK; Crist RC; Ang A; Ambrose-Lanci LM; Lohoff FW; Saxon AJ; Ling W; Hillhouse MP; Bruce RD; Woody G; Berrettini WH
Pharmacogenomics J; 2014 Jun; 14(3):303-8. PubMed ID: 24126707
[TBL] [Abstract][Full Text] [Related]
5. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
6. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.
Crist RC; Li J; Doyle GA; Gilbert A; Dechairo BM; Berrettini WH
Am J Drug Alcohol Abuse; 2018; 44(4):431-440. PubMed ID: 29333880
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone.
Kazi I; Chenoweth MJ; Jutras-Aswad D; Ahamad K; Socias ME; Le Foll B; Tyndale RF
Clin Pharmacol Ther; 2024 Mar; 115(3):506-514. PubMed ID: 38009933
[TBL] [Abstract][Full Text] [Related]
9. The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients.
Thomas PS; Nielsen EM; Spellicy CJ; Harding MJ; Ye A; Patriquin M; Hamon SC; Kosten TR; Nielsen DA
Psychiatr Genet; 2021 Jun; 31(3):88-94. PubMed ID: 33953123
[TBL] [Abstract][Full Text] [Related]
10. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
Hser YI; Evans E; Huang D; Weiss R; Saxon A; Carroll KM; Woody G; Liu D; Wakim P; Matthews AG; Hatch-Maillette M; Jelstrom E; Wiest K; McLaughlin P; Ling W
Addiction; 2016 Apr; 111(4):695-705. PubMed ID: 26599131
[TBL] [Abstract][Full Text] [Related]
12. Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations.
Crist RC; Ambrose-Lanci LM; Vaswani M; Clarke TK; Zeng A; Yuan C; Ferraro TN; Hakonarson H; Kampman KM; Dackis CA; Pettinati HM; O'Brien CP; Oslin DW; Doyle GA; Lohoff FW; Berrettini WH
Drug Alcohol Depend; 2013 Jan; 127(1-3):122-8. PubMed ID: 22795689
[TBL] [Abstract][Full Text] [Related]
13. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
[TBL] [Abstract][Full Text] [Related]
14. Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder.
Crist RC; Phillips KA; Furnari MA; Moran LM; Doyle GA; McNicholas LF; Cornish JW; Kampman KM; Preston KL; Berrettini WH
Pharmacogenomics J; 2019 Jun; 19(3):260-268. PubMed ID: 30368523
[TBL] [Abstract][Full Text] [Related]
15. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
Soyka M; Hillemacher T
Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
[No Abstract] [Full Text] [Related]
16. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
[TBL] [Abstract][Full Text] [Related]
17. Opioid agonist treatment for pharmaceutical opioid dependent people.
Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
[TBL] [Abstract][Full Text] [Related]
18. Narrative review: buprenorphine for opioid-dependent patients in office practice.
Sullivan LE; Fiellin DA
Ann Intern Med; 2008 May; 148(9):662-70. PubMed ID: 18458279
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
20. Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial.
McAnulty C; Bastien G; Ledjiar O; Eugenia Socias M; Le Foll B; Lim R; Jutras-Aswad D;
Addict Behav; 2024 Jul; 154():108023. PubMed ID: 38579594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
